| Efficient generation and selection of virtual populations in quantitative systems pharmacology models RJ Allen, TR Rieger, CJ Musante CPT: pharmacometrics & systems pharmacology 5 (3), 140-146, 2016 | 141 | 2016 |
| Mathematical modeling of the eukaryotic heat-shock response: dynamics of the hsp70 promoter TR Rieger, RI Morimoto, V Hatzimanikatis Biophysical journal 88 (3), 1646-1658, 2005 | 112 | 2005 |
| Improving the generation and selection of virtual populations in quantitative systems pharmacology models TR Rieger, RJ Allen, L Bystricky, Y Chen, GW Colopy, Y Cui, A Gonzalez, ... Progress in biophysics and molecular biology 139, 15-22, 2018 | 69 | 2018 |
| Bistability explains threshold phenomena in protein aggregation both in vitro and in vivo TR Rieger, RI Morimoto, V Hatzimanikatis Biophysical journal 90 (3), 886-895, 2006 | 31 | 2006 |
| Transforming translation through quantitative pharmacology for high‐impact decision making in drug discovery and development N Gupta, D Bottino, USH Simonsson, CJ Musante, T Bueters, TR Rieger, ... Clinical Pharmacology & Therapeutics 107 (6), 1285-1289, 2020 | 10 | 2020 |
| Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy TR Rieger, CJ Musante European Journal of Pharmaceutical Sciences 94, 15-19, 2016 | 9 | 2016 |
| Modeling is data driven: use it for successful virtual patient generation TR Rieger, RJ Allen, CJ Musante CPT: Pharmacometrics & Systems Pharmacology 10 (5), 393-394, 2021 | 8 | 2021 |
| Efficient generation and selection of virtual populations in quantitative systems pharmacology models. CPT Pharmacomet Syst Pharmacol 5 (3): 140–146 RJ Allen, TR Rieger, CJ Musante | 7 | 2016 |
| Opportunities and Challenges of Disease Progression Modeling in Drug Development–An IQ Perspective K Goteti, N Hanan, M Magee, J Wojciechowski, S Mensing, B Lalovic, ... Clinical Pharmacology & Therapeutics 114 (2), 266-274, 2023 | 3 | 2023 |
| QSP modeling of liver AMPK activation using NAFLDsym is predicted to reduce steatosis in NAFLD patients G Generaux, TR Rieger, BA Howell, RJ Allen, CJ Musante, PB Watkins, ... Clin Pharmacol The 101, 65S, 2017 | 2 | 2017 |
| A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease TR Rieger, RJ Allen, CJ Musante Frontiers in Pharmacology 13, 910789, 2022 | 1 | 2022 |
| Even More Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models TR Rieger, RJ Allen, L Bystricky, Y Chen, G Colopy, Y Cui, A Gonzalez, ... J Pharmacokinet Pharmacodyn 44, S115-S115, 2017 | 1 | 2017 |
| Using systems pharmacology modeling to understand the pathophysiology of NAFLD and response to dietary intervention in a simulated population SQ Siler, TR Rieger, G Generaux, BA Howell, RJ Allen, CJ Musante, ... Clin Pharmacol Ther 101 (S1), S88, 2017 | 1 | 2017 |
| Assessment of the therapeutic potential of GLP‐1+ GIP using an integrated model of human metabolism T Rieger, D Tess, J Jones Assessment 1000, 031, 2014 | 1 | 2014 |
| ASSESSING CLINICAL EFFICACY AND TRIAL DESIGN PARAMETERS FOR TREATMENTS OF NON-ALCOHOLIC FATTY LIVER DISEASE USING A NOVEL QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL. TR Rieger, RJ Allen, CJ Musante CLINICAL PHARMACOLOGY & THERAPEUTICS 105, S110-S110, 2019 | | 2019 |
| QSP MODELING OF LIVER DGAT INHIBITION USING NAFLDSYM IS PREDICTED TO REDUCE STEATOSIS BUT MAY NOT RELIEVE LIPOTOXICITY IN NAFLD PATIENTS TR Rieger, G Generaux, BA Howell, R Allen, CJ Musante, PB Watkins, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 101 (S 1), S85-S85, 2017 | | 2017 |
| Predicting the safety and efficacy of inhibition of diacylglycerol transferase 2 for the treatment of non-alcoholic fatty liver disease T Rieger, S Siler, G Generaux, B Howell, R Allen, C Musante JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 43, S79-S79, 2016 | | 2016 |
| Quantitative systems pharmacology approaches to increase confidence in rationale for drug discovery and development programs CJ Musante, R Allen, TR Rieger, WC Thompson DRUG METABOLISM REVIEWS 48, 11-11, 2016 | | 2016 |
| An in silico approach to identification of pathways involved in dermal aging aimed at antiaging intervention K Kudrycki, A Lo, L Shoda, T Rieger JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 68 (4), AB27-AB27, 2013 | | 2013 |
Vassily HatzimanikatisAssociate Professor, EPFLBestätigte E-Mail-Adresse bei epfl.ch
